Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Medication adherence after pediatric allogeneic stem cell transplantation: Barriers and facilitators.

Hoegy D, Bleyzac N, Rochet C, De Freminville H, Rénard C, Kébaili K, Bertrand Y, Dussart C, Janoly-Dumenil A.

Eur J Oncol Nurs. 2019 Feb;38:1-7. doi: 10.1016/j.ejon.2018.11.006. Epub 2018 Nov 23.

PMID:
30717930
2.

A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Tod M, Goutelle S, Bleyzac N, Bourguignon L.

Clin Pharmacokinet. 2018 Sep 8. doi: 10.1007/s40262-018-0711-0. [Epub ahead of print]

PMID:
30194612
3.

Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.

Philippe M, Neely M, Rushing T, Bertrand Y, Bleyzac N, Goutelle S.

Bone Marrow Transplant. 2018 Aug 14. doi: 10.1038/s41409-018-0281-7. [Epub ahead of print]

PMID:
30108322
4.

Increased Risk of Thrombosis Associated with Peripherally Inserted Central Catheters Compared with Conventional Central Venous Catheters in Children with Leukemia.

Noailly Charny PA, Bleyzac N, Ohannessian R, Aubert E, Bertrand Y, Renard C.

J Pediatr. 2018 Jul;198:46-52. doi: 10.1016/j.jpeds.2018.03.026. Epub 2018 Apr 27.

PMID:
29709343
5.

Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Fermier N, Bourguignon L, Goutelle S, Bleyzac N, Tod M.

Clin Pharmacokinet. 2018 Dec;57(12):1581-1591. doi: 10.1007/s40262-018-0651-8.

PMID:
29572664
7.

Continuous intravenous vancomycin in children with normal renal function hospitalized in hematology-oncology: prospective validation of a dosing regimen optimizing steady-state concentration.

Hoegy D, Goutelle S, Garnier N, Rénard C, Faure-Conter C, Bergeron C, Bertrand Y, Bleyzac N.

Fundam Clin Pharmacol. 2018 Jun;32(3):323-329. doi: 10.1111/fcp.12344. Epub 2018 Mar 24.

PMID:
29315849
8.

Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism.

Cerruti L, Bleyzac N, Tod M.

Clin Pharmacokinet. 2018 Jul;57(7):831-841. doi: 10.1007/s40262-017-0596-3.

PMID:
28889370
9.

Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?

Tod M, Goutelle S, Bourguignon L, Bleyzac N.

CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):226. doi: 10.1002/psp4.12164. Epub 2017 Apr 11. No abstract available.

10.

A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.

Tod M, Bourguignon L, Bleyzac N, Goutelle S.

AAPS J. 2017 Mar;19(2):497-509. doi: 10.1208/s12248-016-0021-0. Epub 2016 Dec 6.

PMID:
27924615
11.

A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.

Philippe M, Neely M, Bertrand Y, Bleyzac N, Goutelle S.

Clin Pharmacokinet. 2017 Apr;56(4):435-447. doi: 10.1007/s40262-016-0448-6.

PMID:
27585476
12.

Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.

Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, Schumitzky A, Bleyzac N, Goutelle S.

Ther Drug Monit. 2016 Jun;38(3):332-42. doi: 10.1097/FTD.0000000000000276.

13.

Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.

Bleyzac N, Cuzzubbo D, Rénard C, Garnier N, Dubois V, Domenech C, Goutagny MP, Plesa A, Grardel N, Goutelle S, Janoly-Duménil A, Bertrand Y.

Bone Marrow Transplant. 2016 May;51(5):698-704. doi: 10.1038/bmt.2015.350. Epub 2016 Jan 25.

PMID:
26808568
14.

Pharmacokinetic and Analytical Issues in Busulfan Area Under the Curve Estimation and Simulation.

Philippe M, Bleyzac N, Goutelle S.

Biol Blood Marrow Transplant. 2016 Jan;22(1):185. doi: 10.1016/j.bbmt.2015.09.022. Epub 2015 Sep 30. No abstract available.

15.

Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Philippe M, Goutelle S, Guitton J, Fonrose X, Bergeron C, Girard P, Bertrand Y, Bleyzac N.

Bone Marrow Transplant. 2016 Jan;51(1):72-8. doi: 10.1038/bmt.2015.218. Epub 2015 Sep 21.

PMID:
26389835
16.

[A French survey on the resort of oral alternative complementary medicines used in children with cancer].

Philibert C, Hoegy D, Philippe M, Marec-Bérard P, Bleyzac N.

Bull Cancer. 2015 Oct;102(10):854-62. doi: 10.1016/j.bulcan.2015.06.008. Epub 2015 Sep 19. French.

PMID:
26387822
17.

Impact of a change in protected environment on the occurrence of severe bacterial and fungal infections in children undergoing hematopoietic stem cell transplantation.

Libbrecht C, Goutagny MP, Bacchetta J, Ploton C, Bienvenu AL, Bleyzac N, Mialou V, Bertrand Y, Domenech C.

Eur J Haematol. 2016 Jul;97(1):70-7. doi: 10.1111/ejh.12685. Epub 2015 Dec 1.

PMID:
26380877
18.

Improvement in the Outcome of Invasive Aspergillosis in a Pediatric Hematology Department: A 10-Year Review.

Domenech C, Leick-Courtois C, Bienvenu AL, Pracros JP, Picot S, Bleyzac N, Bertrand Y.

J Pediatr Hematol Oncol. 2015 Oct;37(7):560-5. doi: 10.1097/MPH.0000000000000389.

PMID:
26165404
19.

High methotrexate exposure and toxicity in children with t(9;22) positive acute lymphoblastic leukaemia treated with imatinib.

Loue C, Garnier N, Bertrand Y, Bleyzac N.

J Clin Pharm Ther. 2015 Oct;40(5):599-600. doi: 10.1111/jcpt.12298. Epub 2015 Jun 13.

PMID:
26073789
20.

Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.

Philippe M, Hénin E, Bertrand Y, Plantaz D, Goutelle S, Bleyzac N.

AAPS J. 2015 Sep;17(5):1157-67. doi: 10.1208/s12248-015-9779-8. Epub 2015 May 15.

21.

Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia.

Bleyzac N, Philippe M, Bertrand A, Bertrand Y.

Haematologica. 2015 May;100(5):e211-2. doi: 10.3324/haematol.2014.122275. No abstract available.

22.

Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children.

Bernard E, Goutelle S, Bertrand Y, Bleyzac N.

Ann Pharmacother. 2014 Dec;48(12):1580-4. doi: 10.1177/1060028014550644. Epub 2014 Oct 3.

PMID:
25280976
23.

[Lacidipine efficacy and safety for high blood pressure treatment in pediatric oncohematology].

Bernard E, Mialou V, Dony A, Garnier N, Renard C, Bleyzac N.

Arch Pediatr. 2014 Oct;21(10):1101-5. doi: 10.1016/j.arcped.2014.06.028. Epub 2014 Aug 11. French.

PMID:
25125033
24.

Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile.

Bleyzac N, Kebaili K, Mialou V, Bertrand Y, Goutelle S.

Ther Drug Monit. 2014 Dec;36(6):724-9. doi: 10.1097/FTD.0000000000000084.

PMID:
24739665
25.

Cytomegalovirus infection in pediatric allogenic hematopoietic stem cell transplantation. A single center experience.

Sedky M, Mekki Y, Mialou V, Bleyzac N, Girard S, Salama E, Abdel Rahman H, Bertrand Y.

Pediatr Hematol Oncol. 2014 Nov;31(8):743-53. doi: 10.3109/08880018.2013.859188. Epub 2013 Dec 5.

PMID:
24308761
26.

Salvage therapy of refractory severe aplastic anemia by decreasing cyclosporine dose regimen.

Bertrand A, Philippe M, Bertrand Y, Plantaz D, Bleyzac N.

Eur J Haematol. 2014 Feb;92(2):172-6. doi: 10.1111/ejh.12220. Epub 2013 Dec 2.

PMID:
24147892
27.

In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M.

AAPS J. 2013 Apr;15(2):415-26. doi: 10.1208/s12248-012-9431-9. Epub 2013 Jan 15.

28.

On the importance of blood sampling for ciclosporin pharmacokinetic studies.

Bleyzac N.

Br J Clin Pharmacol. 2013 Mar;75(3):869-70. doi: 10.1111/j.1365-2125.2012.04414.x. No abstract available.

29.

A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection.

Janoly-Dumenil A, Rouvet I, Bleyzac N, Morfin F, Zabot MT, Tod M.

Antimicrob Agents Chemother. 2012 Jul;56(7):3732-8. doi: 10.1128/AAC.06423-11. Epub 2012 Apr 23.

30.

Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.

Paci A, Vassal G, Moshous D, Dalle JH, Bleyzac N, Neven B, Galambrun C, Kemmel V, Abdi ZD, Broutin S, Pétain A, Nguyen L.

Ther Drug Monit. 2012 Apr;34(2):198-208. doi: 10.1097/FTD.0b013e31824c2f60.

PMID:
22406655
31.

The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.

Bourguignon L, Ducher M, Matanza D, Bleyzac N, Uhart M, Odouard E, Maire P, Goutelle S.

Fundam Clin Pharmacol. 2012 Apr;26(2):279-85. doi: 10.1111/j.1472-8206.2011.01000.x. Epub 2011 Oct 17.

PMID:
22004557
32.

Cryptosporidiosis in children with acute lymphoblastic leukemia on maintenance chemotherapy.

Domenech C, Rabodonirina M, Bleyzac N, Pagès MP, Bertrand Y.

J Pediatr Hematol Oncol. 2011 Oct;33(7):570-2. doi: 10.1097/MPH.0b013e31820e2d3a.

PMID:
21941152
33.

Comment: assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.

Goutelle S, Neely M, Bleyzac N.

Ann Pharmacother. 2011 Sep;45(9):1171-2. doi: 10.1345/aph.1P588a. Epub 2011 Aug 23. No abstract available.

PMID:
21862712
34.

[Invasive fungal infections in oncology and haematology unit care: review of literature and costs analysis].

Lecointre R, Bleyzac N.

Ann Pharm Fr. 2011 Jul;69(4):214-20. doi: 10.1016/j.pharma.2011.05.001. Epub 2011 Jul 27. Review. French.

PMID:
21840441
35.

[Vancomycin: what dosages are needed to achieve efficacy in paediatric hematology/oncology?].

Zegbeh H, Bleyzac N, Berhoune C, Bertrand Y.

Arch Pediatr. 2011 Aug;18(8):850-5. doi: 10.1016/j.arcped.2011.05.013. Epub 2011 Jun 12. French.

PMID:
21664803
36.

[Assessment of adherence to Afssaps guidelines for the prescription of antifungals in pediatric hemato-oncology].

Berthe A, Duclos A, Ray-coquard I, Colin C, Bleyzac N.

Med Mal Infect. 2011 Jan;41(1):25-32. doi: 10.1016/j.medmal.2010.09.012. Epub 2010 Nov 17. French.

PMID:
21087832
37.

Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.

Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M.

Pharm Res. 2011 Mar;28(3):531-9. doi: 10.1007/s11095-010-0299-z. Epub 2010 Oct 21.

PMID:
20963627
38.

Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.

Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M.

Pharm Res. 2010 Dec;27(12):2602-13. doi: 10.1007/s11095-010-0252-1. Epub 2010 Sep 2.

PMID:
20811933
39.

Oral voriconazole dose in children: one size does not fit all.

Goutelle S, Larcher R, Padoin C, Mialou V, Bleyzac N.

Clin Infect Dis. 2010 Oct 1;51(7):870; author reply 871. doi: 10.1086/656293. No abstract available.

PMID:
20809842
40.

High-dose ganciclovir in HHV-6 encephalitis of an immunocompetent child.

Olli-Lähdesmäki T, Haataja L, Parkkola R, Waris M, Bleyzac N, Ruuskanen O.

Pediatr Neurol. 2010 Jul;43(1):53-6. doi: 10.1016/j.pediatrneurol.2010.02.003.

PMID:
20682205
41.

Effect of duration and intensity of ganciclovir exposure on lymphoblastoid cell toxicity.

Janoly-Dumenil A, Rouvet I, Bleyzac N, Bertrand Y, Aulagner G, Zabot MT.

Antivir Chem Chemother. 2009;19(6):257-62.

PMID:
19641234
42.

The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.

Bleyzac N.

Fundam Clin Pharmacol. 2008 Dec;22(6):605-8. doi: 10.1111/j.1472-8206.2008.00652.x.

PMID:
19049662
43.

Human cytomegalovirus (HCMV) laryngitis: atypical HCMV disease presentation in haematopoietic stem cell transplantation.

Valla F, Lévêque N, Escuret V, Galambrun C, Mialou V, Bleyzac N, Bertrand Y.

J Med Microbiol. 2008 Nov;57(Pt 11):1434-5. doi: 10.1099/jmm.0.2008/001313-0. No abstract available.

PMID:
18927426
44.

Continuous infusion of methylprednisolone via paediatric parenteral nutrition: a pharmacokinetic animal study.

Gellis C, Sautou-Miranda V, Bleyzac N, Jarrige JF, Minet-Quinard R, Chopineau J.

Clin Nutr. 2007 Aug;26(4):491-7. Epub 2007 Apr 17.

PMID:
17442463
45.

Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.

Bertholle-Bonnet V, Bleyzac N, Galambrun C, Mialou V, Bertrand Y, Souillet G, Aulagner G.

Ther Drug Monit. 2007 Apr;29(2):177-84.

PMID:
17417071
46.

[Human herpesvirus 6 encephalitis after bone marrow transplantation].

Pop-Jora D, Berhoune C, Najioullah F, Girard S, Mialou V, Bleyzac N, Galambrun C, Bertrand Y.

Arch Pediatr. 2006 Dec;13(12):1518-20. Epub 2006 Nov 7. French.

PMID:
17092696
47.

Human herpes virus-6 encephalitis in a paediatric bone marrow recipient: successful treatment with pharmacokinetic monitoring and high doses of ganciclovir.

Janoly-Duménil A, Galambrun C, Basset T, Mialou V, Bertrand Y, Bleyzac N.

Bone Marrow Transplant. 2006 Dec;38(11):769-70. Epub 2006 Oct 2. No abstract available.

PMID:
17013421
48.

Efficacy and plasma levels of ropivacaine for children: controlled regional analgesia following lower limb surgery.

Duflo F, Sautou-Miranda V, Pouyau A, Taylor P, Combet S, Chotel F, Bleyzac N, Chassard D.

Br J Anaesth. 2006 Aug;97(2):250-4. Epub 2006 Jun 19.

49.

Erythromycin promotes gastric emptying during acute pain in volunteers.

Bouvet L, Duflo F, Bleyzac N, Mion F, Boselli E, Allaouchiche B, Chassard D.

Anesth Analg. 2006 Jun;102(6):1803-8.

PMID:
16717329
50.

Two cases of varicella zoster virus meningitis found in pediatric patients after bone marrow transplantation despite valaciclovir prophylaxis and without skin lesions.

Lévêque N, Galambrun C, Najioullah F, Bleyzac N, Pages MP, Bertrand Y.

J Med Virol. 2006 Apr;78(4):514-6.

PMID:
16482541

Supplemental Content

Loading ...
Support Center